Text Size

Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment

Oddone F, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Holló G; VISIONARY Study Group


  • 2022
  • Advances in Therapy
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Glaucoma Unit, IRCSS-Fondazione Bietti, Rome, Italy; Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Portsmouth, UK; Instituto Oftalmologico Gomez-Ulla, Calle Maruxa Mallo 3 Santiago de Compostela, Galicia, Spain; LLC Vzglyad, Leningradskaya, Chita, Russia; Santen SA, Geneva, Switzerland; Tutkimusz Ltd, Solymár, Hungary; Eye Center, Prima Medica Health Centers, Budapest, Hungary

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.


Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.


Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022